High incidence of cardiovascular events in patients with rheumatoid arthritis.

1. Abe M. Complement activation and inflammation. Rinsho Byori 2006;54:744–56. 2. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide Study. N Engl J Med 2007;357:1199–209. 3. Kurreeman FA, Padyukov L, Marques RB, Schordi SJ, Seddighzadeh M, StoekenRijsbergen G, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 2007;4:e278. 4. Kurreeman FA, Rocha D, Houwing-Duistermaat J, Vrijmoet S, Teixeira VH, Migliorini P, et al. Replication of the tumor necrosis factor receptor-associated factor1/ complement component 5 region as a susceptibility locus for rheumatoid arthritis in a European family-based study. Arthritis Rheum 2008;58:2670–4. 5. Larsson A, Sjöquist J. Binding of complement component C5 to model immune complexes and the use of anti-C5 antibodies for determination of C5-containing circulating immune complexes. J Clin Lab Immunol 1989;28:5–9. 6. Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999;36:905–14. 7. Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collageninduced arthritis. J Immunol 2000;164:4340–7. 8. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995;92:8955–9. 9. Ji H, Gauguier D, Ohmura K, Gonzalez A, Duchatelle V, Danoy P, et al. Genetic influences on the end-stage effector phase of arthritis. J Exp Med 2001;194:321–30. 10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.